Shanghai Sanyou Medical (688085) Fundamentals 2026 — P/E 72.5x, Revenue Analysis | SniperIQ
Shanghai Sanyou Medical (688085) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of ¥4.6B, trading at ¥12.50 on the SHH. This SniperIQ fundamentals page covers Shanghai Sanyou Medical's valuation (P/E 72.5x, P/B 2.0x), profitability (net margin 10.5%), revenue (¥543M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shanghai Sanyou Medical's market cap?
Shanghai Sanyou Medical (688085) has a market capitalization of approximately ¥4.6B, trading at ¥12.50 on the SHH. Market cap moves with the live share price.
What is Shanghai Sanyou Medical's P/E ratio?
Shanghai Sanyou Medical's trailing twelve-month P/E ratio is 72.5x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shanghai Sanyou Medical?
Shanghai Sanyou Medical runs a net profit margin of 10.5%, a gross margin of 99.4%, and an operating margin of 7.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shanghai Sanyou Medical generate?
Shanghai Sanyou Medical reported revenue of ¥543M for fiscal year 2025, with net income of ¥63M and earnings per share (EPS) of 0.19. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shanghai Sanyou Medical pay a dividend?
Shanghai Sanyou Medical offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shanghai Sanyou Medical financially healthy?
Shanghai Sanyou Medical carries a debt-to-equity ratio of 0.02x and a current ratio of 5.85x, with a market beta of 0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shanghai Sanyou Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shanghai Sanyou Medical (688085) the key facts are: market cap ¥4.6B, P/E 72.5x, revenue ¥543M, 52-week range 11.12-23.75455. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shanghai Sanyou Medical's full fundamentals live
Get Shanghai Sanyou Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.